Status:
COMPLETED
Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The aim of the study is to investigate the effect of ciclesonide versus fluticasone propionate versus placebo on airway hyperresponsiveness and on the hypothalamic-pituitary-adrenal axis (HPA axis). T...
Eligibility Criteria
Inclusion
- Main
- Patients who have had a history of bronchial asthma for at least 6 months
- FEV1 \>60% of predicted for at least 24 h
- Patients who are hyperresponsive to methacholine and to AMP
- Patients who are in good health with the exception of asthma
- Main
Exclusion
- Concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids
- Patients suffering from COPD and/or other relevant lung diseases except asthma
- Current smokers and ex-smokers both with ≥10 pack years
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00163332
Start Date
March 1 2003
Last Update
December 6 2016
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Altana Pharma/Nycomed
Genk, Belgium, 3600
2
Altana Pharma/Nycomed
Ghent, Belgium, 9000
3
Altana Pharma/Nycomed
Lanaken, Belgium, 3620
4
Altana Pharma/Nycomed
Liège, Belgium, 4000